Skip to main content
SpringerLink
Log in

Anakinra/canakinumab

Various toxicities: 6 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Identifying patients demographics have been obtained through direct communication with the author.

Reference

  • Atas N, et al. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients. Clinical and Experimental Rheumatology 39: S30-S36, No. 5, Sep 2021. Available from: URL: https://www.clinexprheumatol.org/abstract.asp?a=16847

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anakinra/canakinumab. Reactions Weekly 1913, 45 (2022). https://doi.org/10.1007/s40278-022-18195-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-18195-4

Search

Navigation